Eir Ventures
Eir Ventures is a Nordic venture capital firm backing early-stage life science companies across biotech, medtech, diagnostics and digital health, with offices in Stockholm and Copenhagen.
Eir Ventures is a Stockholm venture capital firm with 14 active companies and 1 exit.
Sector breakdown
15 companiesGeography breakdown
4 geographiesKey facts
Recent exits
Eir Ventures took Cinclus Pharma public in 2024 after 2 years.
Coverage notes
1 fund tracked, 15 portfolio companies (14 active · 1 realized). Verified weekly from public filings and deal announcements.
Funds & portfolio
Every fund Eir Ventures has raised, with its portfolio companies. Hand-checked from public filings.
Eir Ventures IHarvestingLife Sciences VC2020€122M14 assets1 exitsLife Sciences VC2020 · 6yr€122M141
Unrealized
14 held| Company | Entry |
|---|---|
| ArgusEye MedTech · Sweden | 2021 |
| Attgeno Biotech · Sweden | 2022 |
| Dania Tx Biotech · Denmark | 2023 |
| GutCRINE Biotech · Denmark | 2023 |
| Henlez Biotech · Denmark | 2022 |
| Hoba Therapeutics Biotech · Denmark | 2022 |
| Moleculent Biotech · Sweden | 2024 |
| Pretzel Therapeutics Biotech · US | 2022 |
| Purpose Pharma Pharma · Sweden | 2024 |
| RAPP HealthTech · Sweden | 2023 |
| SACRA Therapeutics Biotech · Sweden | 2021 |
| Scenic Biotech Biotech · Netherlands | 2023 |
| Sortina Pharma Biotech · Sweden | 2020 |
| Strike Pharma Biotech · Sweden | 2022 |
Realized
1 exit| Company | Entry | Exit | Type | Buyer | MOIC |
|---|---|---|---|---|---|
| Cinclus Pharma Pharma · Sweden | 2022 | 2024 | IPO | – | – |
About Eir Ventures
Eir Ventures is a dedicated Nordic life sciences venture capital firm with approximately €122 million of assets under management as of December 2024 (Eir Ventures I final close December 2021 at €122.3 million), headquartered in Stockholm with a second office in Copenhagen. The firm was founded in 2020 by founding partners Stephan Christgau and Magnus Persson and operates as a partner-owned independent firm backed by EIF, Novo Holdings, Saminvest, Vaekstfonden, Nordic universities and family offices.
Investment thesis
Eir Ventures deploys capital through one active fund (Eir Ventures I, with approximately 12-20 portfolio investments), targeting early-stage and selectively later-stage life sciences venture capital with active ownership including board seats and company creation. The investment triad emphasises transformative potential, execution excellence and scalability. Sector focus spans biotech and therapeutics, innovative medicine, drug delivery, rare diseases, healthtech and diagnostics. Geographic deployment is anchored in the Nordics (Sweden, Denmark, Finland, Norway) with a global syndication network spanning Europe and the US, sourcing from leading regional universities and incubators.
Recent activity
Recent realised exits include biotech and pharma IPO (2024). Recent acquisitions include drug delivery and pharma (2024), with no new platform investments publicly recorded in 2025-2026 as the firm focuses on portfolio support. The platform continues active deployment across the Nordic life sciences mandate.
Frequently asked questions
- What investment strategy does Eir Ventures focus on?
- Eir Ventures focuses on VC strategies in the private equity space.
- How many portfolio companies does Eir Ventures have?
- Eir Ventures has 14 active portfolio companies and 1 completed exit and 1 fund tracked on GP Intel.
- Where is Eir Ventures headquartered?
- Eir Ventures is headquartered in Stockholm, Sweden.
- When was Eir Ventures founded?
- Eir Ventures was founded in 2020.
- What sectors does Eir Ventures invest in?
- Eir Ventures invests across Healthcare.
Similar firms
Other private equity firms tracked on GP Intel.
Sweden·€3.2B
Sweden·€2.9BSweden·€2.3BSweden·€1.4B
Sweden·€500MSweden·€397MSweden·€351MSweden·€300M
Sweden·€188M
Sweden·€125MSweden·€115MSweden·€92M